AIRFLOW 50 INH: Dual-Action Relief for Asthma & COPD

 AIRFLOW 50 INH, manufactured by Steris Healthcare, is a combination respiratory inhalation therapy formulated with Salmeterol and Fluticasone Propionate Powder for Inhalation IP. This dry powder inhaler combines a long-acting beta2-agonist (LABA) with an inhaled corticosteroid (ICS) to provide comprehensive management of chronic respiratory conditions such as asthma and Chronic Obstructive Pulmonary Disease (COPD). AIRFLOW 50 INH is prescribed for the regular, twice-daily maintenance treatment of airway obstruction and inflammation, helping patients breathe more easily and reduce the frequency of respiratory flare-ups.

Why It's Important

Asthma and COPD are chronic inflammatory airway conditions where the bronchial passages become narrowed, inflamed, and prone to spasm, making breathing difficult and unpredictable. Managing these conditions effectively requires addressing two separate problems simultaneously: the underlying airway inflammation and the muscular tightening (bronchoconstriction) that restricts airflow. Using a bronchodilator alone without an anti-inflammatory agent can leave the underlying inflammation unchecked, while using a steroid alone may not adequately relieve acute airway tightness. This is why a combination therapy like AIRFLOW 50 INH is clinically significant — it tackles both mechanisms at once, offering more consistent symptom control than either component could provide individually. Regular use helps reduce the frequency and severity of asthma attacks or COPD exacerbations, improves lung function over time, and supports a better overall quality of life for patients managing chronic respiratory disease.

Key Benefits 

What Are the Benefits of This Combination?

• Provides sustained, long-acting bronchodilation for up to 12 hours per dose
• Reduces airway inflammation, addressing the root cause of asthma and COPD symptoms
• Helps decrease the frequency of asthma attacks and COPD exacerbations
• Improves overall lung function and airflow with regular, consistent use
• Reduces reliance on short-acting rescue inhalers when used as directed maintenance therapy
• Supports better sleep quality by controlling nighttime and early-morning symptoms
• Convenient twice-daily dosing in a single dry powder inhaler device

Side Effects

As with most inhaled respiratory therapies, AIRFLOW 50 INH may cause side effects in some patients, particularly when treatment is initiated. Commonly reported effects include throat irritation, hoarseness of voice, headache, oral thrush (a fungal infection in the mouth), and mild tremors. Rinsing the mouth with water after each use can help reduce the risk of oral thrush and throat irritation.

Serious Side Effects

Though less common, patients should seek immediate medical attention if they experience signs of a severe allergic reaction (swelling of the face, lips, or throat, difficulty breathing, skin rash), sudden worsening of breathing difficulty immediately after inhalation (paradoxical bronchospasm), irregular or rapid heartbeat, vision changes or eye pain (which may indicate increased eye pressure), or signs of adrenal suppression with long-term use (unusual fatigue, weakness, low blood pressure). Any of these symptoms warrant prompt medical evaluation.

Available Substitutes

Several Salmeterol and Fluticasone Propionate combination inhalers are available in the Indian respiratory therapy market, differing in device type (dry powder inhaler vs. metered-dose inhaler) and dosage strength. Patients should not switch between different inhaler brands or devices without consulting their physician, as inhaler technique and delivered dose can vary significantly between devices, affecting treatment efficacy. For a Steris Healthcare-manufactured alternative or a different strength, patients and PCD franchise partners are encouraged to consult the company's product portfolio directly.

Dosage Guidelines 

Dosage must always be individualized by a physician based on the severity of the patient's respiratory condition and response to therapy. AIRFLOW 50 INH is typically administered as one inhalation twice daily, approximately 12 hours apart, using the dry powder inhaler device as directed. Patients should be properly trained on correct inhaler technique to ensure adequate drug delivery to the lungs. It should be used regularly, even when symptoms are not present, as it is intended for maintenance therapy rather than immediate relief of acute breathing difficulty.

Precautions & Warnings

AIRFLOW 50 INH is not intended for the relief of acute bronchospasm or sudden asthma attacks — a fast-acting rescue inhaler should be used for immediate symptom relief. It should be used with caution in patients with cardiovascular disease, hypertension, diabetes, thyroid disorders, or a history of seizures. Long-term use of the corticosteroid component may increase the risk of reduced bone mineral density, cataracts, or glaucoma, so periodic monitoring is advisable. Patients should not stop this medication abruptly without medical guidance, as doing so can lead to worsening of underlying respiratory disease. It should be used cautiously in pregnant or breastfeeding women, and only under medical supervision. Rinsing the mouth after each use is recommended to minimize local side effects.

How to Use & Mechanism of Action

AIRFLOW 50 INH should be administered using the dry powder inhaler device exactly as demonstrated by a healthcare provider, typically as one inhalation twice daily at consistent times. Its effectiveness comes from the complementary actions of its two components. Salmeterol, a long-acting beta2-adrenergic agonist, works by relaxing the smooth muscles surrounding the airways, providing sustained bronchodilation that keeps air passages open for an extended period. Fluticasone Propionate, an inhaled corticosteroid, works by reducing inflammation within the airway lining, suppressing the release of inflammatory mediators, and decreasing swelling and mucus production. Together, these two mechanisms address both the structural narrowing and the underlying inflammatory process of chronic respiratory disease, offering more complete and lasting symptom control than either agent alone.

Conclusion

AIRFLOW 50 INH by Steris Healthcare offers a clinically established, dual-action approach to managing chronic asthma and COPD through the combined effects of Salmeterol and Fluticasone Propionate Powder for Inhalation IP. By simultaneously addressing airway inflammation and bronchoconstriction, it helps patients achieve more consistent symptom control, improved lung function, and fewer disease flare-ups. As this is a maintenance therapy rather than a rescue medication, correct inhaler technique and consistent, physician-guided use are essential for achieving optimal respiratory outcomes.